Citadel Advisors LLC bought a new position in shares of Global Medical REIT Inc (NYSE:GMRE) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 51,246 shares of the company’s stock, valued at approximately $421,000.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. BlackRock Inc. lifted its stake in Global Medical REIT by 4.2% during the 4th quarter. BlackRock Inc. now owns 831,902 shares of the company’s stock worth $6,822,000 after acquiring an additional 33,411 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Global Medical REIT by 20.1% during the 4th quarter. Bank of New York Mellon Corp now owns 175,081 shares of the company’s stock worth $1,436,000 after acquiring an additional 29,326 shares in the last quarter. Rational Advisors LLC acquired a new position in Global Medical REIT during the 4th quarter worth about $614,000. RMR Advisors LLC lifted its stake in Global Medical REIT by 169.0% during the 4th quarter. RMR Advisors LLC now owns 345,330 shares of the company’s stock worth $2,832,000 after acquiring an additional 216,943 shares in the last quarter. Finally, SG Americas Securities LLC lifted its stake in Global Medical REIT by 67.2% during the 4th quarter. SG Americas Securities LLC now owns 21,463 shares of the company’s stock worth $176,000 after acquiring an additional 8,624 shares in the last quarter. 44.55% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Global Medical REIT Inc (NYSE:GMRE) opened at $7.08 on Friday. The company has a current ratio of 0.22, a quick ratio of 0.22 and a debt-to-equity ratio of 0.72. Global Medical REIT Inc has a 1-year low of $6.45 and a 1-year high of $10.25. The firm has a market capitalization of $153.58, a PE ratio of -41.64, a price-to-earnings-growth ratio of 1.12 and a beta of 1.04.
GMRE has been the topic of several research reports. Zacks Investment Research raised Global Medical REIT from a “hold” rating to a “buy” rating and set a $9.50 target price on the stock in a research note on Tuesday, January 9th. Cantor Fitzgerald initiated coverage on Global Medical REIT in a research note on Wednesday. They set a “buy” rating and a $12.00 target price on the stock. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Global Medical REIT presently has a consensus rating of “Buy” and a consensus price target of $10.10.
TRADEMARK VIOLATION WARNING: “Citadel Advisors LLC Invests $421,000 in Global Medical REIT Inc (GMRE) Stock” was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.tickerreport.com/banking-finance/3254811/citadel-advisors-llc-invests-421000-in-global-medical-reit-inc-gmre-stock.html.
About Global Medical REIT
Global Medical REIT Inc is engaged primarily in the acquisition of licensed, purpose-built healthcare facilities and the leasing of these facilities to clinical operators with market share. The Company’s strategy is to produce increasing, reliable rental revenue by expanding its portfolio, and leasing its healthcare facilities to market operators under long-term triple-net leases.
Want to see what other hedge funds are holding GMRE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Medical REIT Inc (NYSE:GMRE).
Receive News & Ratings for Global Medical REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Medical REIT and related companies with MarketBeat.com's FREE daily email newsletter.